-
Product Insights
NewLikelihood of Approval Analysis for Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that the drugs in Keratoconjunctivitis Sicca (Dry Eye) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Keratoconjunctivitis Sicca (Dry Eye) Overview Keratoconjunctivitis sicca (KCS), also called...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cyclosporine in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cyclosporine in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cyclosporine in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Cyclosporine is...
-
Company Profile
Oyster Point Pharma Inc – Company Profile
Oyster Point Pharma Inc (Oyster Point), a subsidiary of Viatris Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat ocular surface diseases. The company's lead product candidate OC-01 (varenicline solution), a nicotinic acetylcholine receptors (nAChR) that used to developed as a preservative-free nasal spray to treat the indications and symptoms of dry eye disease (DED). Oyster Point OC-01 is designed to re-establish tear film homeostasis that stimulates the trigeminal parasympathetic nervous...
Add to Basket -
Company Profile
NewTrukera Medical – Company Profile
Trukera Medical (Trukera), formerly TearLab Corp, is an in-vitro diagnostic company that focuses on ophthalmic devices. It commercializes a proprietary in vitro diagnostic tear testing platform. The company’s flagship product TearLab osmolarity system measures the osmolarity of human tears to aid in the diagnosis of dry eye disease (DED) in patients. Its osmolarity system is a CE marked and the US FDA cleared device. Trukera conducts research and development activities through its wholly-owned subsidiary, TearLab Research Inc. It sells products...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OTX-DED
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OTX-DED Drug Details Dexamethasone is under development for the treatment of episodic dry eye...
-
Product Insights
Net Present Value Model: Xiidra
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xiidra Drug Details Lifitegrast (Xiidra) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – simpinicline citrate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry simpinicline citrate Drug Details Simpinicline citrate (OC-02) is under development for the treatment of...
-
Product Insights
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants. The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...